Cover Image
市場調查報告書

糞腸球菌感染疾病的開發中產品分析

Enterococcus faecium Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 229790
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
糞腸球菌感染疾病的開發中產品分析 Enterococcus faecium Infections - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 126 Pages
簡介

腸球菌是人畜一般腸內細菌菌種的一部分。同時也是造成嚴重感染病的重要病原體。腸球菌種有被尿道感染症及菌血症,心內膜炎,腦膜炎等各種感染疾病引起的可能性。

本報告提供全球各國治療糞腸球菌(糞腸球菌,腸內球菌)感染疾病用的開發中產品開發情形相關分析,彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)進展狀況),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

糞腸球菌感染疾病概要

治療藥的開發

  • 肝臟病開發中產品:概要
  • 肝臟病開發中產品:比較分析

各企業正開發中的糞腸球菌感染疾病治療藥

大學/研究機關研究中的糞腸球菌感染疾病治療藥

開發中產品概要

  • 初期階段的產品
  • 不明確的階段有的產品

糞腸球菌感染疾病治療藥:開發中產品一覽(各企業)

糞腸球菌感染疾病治療藥:研究中產品一覽(大學/研究機關別)

糞腸球菌感染疾病治療藥的開發企業

  • 大日本住友製藥
  • Aquapharm Biodiscovery Limited
  • Cellceutix Corporation
  • Omnia Molecular Ltd.
  • Biota Pharmaceuticals, Inc.
  • Abgentis Limited
  • Melinta Therapeutics Inc.

糞腸球菌感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子種類別
  • 各治療分類

藥物簡介

  • RX-04
  • AQP-182
  • SM-295291
  • SM-369926
  • EnteroVAX
  • RX-05
  • Chrysophaentin抗生素
  • brilacidin
  • Compound-1
  • Eskape Bacteria Project

糞腸球菌感染疾病治療藥:最新的藥物簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7223IDB

Summary

Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H2 2015', provides an overview of the Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Enterococcus faecium Infections Overview
  • Therapeutics Development
    • Pipeline Products for Enterococcus faecium Infections - Overview
    • Pipeline Products for Enterococcus faecium Infections - Comparative Analysis
  • Enterococcus faecium Infections - Therapeutics under Development by Companies
  • Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes
  • Enterococcus faecium Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Enterococcus faecium Infections - Products under Development by Companies
  • Enterococcus faecium Infections - Products under Investigation by Universities/Institutes
  • Enterococcus faecium Infections - Companies Involved in Therapeutics Development
    • Alchemia Limited
    • Alvogen Korea
    • Aphios Corporation
    • BioSource Pharm, Inc.
    • Cellceutix Corporation
    • ContraFect Corporation
    • Helix BioMedix, Inc.
    • Hsiri Therapeutics, LLC
    • LegoChem Biosciences, Inc
    • Lytix Biopharma AS
    • Melinta Therapeutics, Inc
    • MGB Biopharma Limited
    • Microbiotix, Inc.
    • MicuRx Pharmaceuticals, Inc.
    • NovaBay Pharmaceuticals, Inc.
    • Novan, Inc.
    • NovoBiotic Pharmaceuticals, LLC
    • Omnia Molecular Ltd.
    • Oragenics, Inc.
    • Sealife PHARMA GMBH
    • Sentinella Pharmaceuticals, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • TAXIS Pharmaceuticals, Inc.
    • Wockhardt Limited
  • Enterococcus faecium Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BSPC-728 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-304 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chrysophaentin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • closthioamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Epimerox - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCB-010371 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCB-010699 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Marinus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-1162 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-IV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MU-1140 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAI-107 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAI-603 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVN-1000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OM-011818 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-05 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-873 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-2078 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Teixobactin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WCK-4086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Enterococcus faecium Infections - Recent Pipeline Updates
  • Enterococcus faecium Infections - Dormant Projects
  • Enterococcus faecium Infections - Discontinued Products
  • Enterococcus faecium Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
      • Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
      • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
      • Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins
      • May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
      • Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Enterococcus faecium Infections, H2 2015
  • Number of Products under Development for Enterococcus faecium Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Enterococcus faecium Infections - Pipeline by Alchemia Limited, H2 2015
  • Enterococcus faecium Infections - Pipeline by Alvogen Korea, H2 2015
  • Enterococcus faecium Infections - Pipeline by Aphios Corporation, H2 2015
  • Enterococcus faecium Infections - Pipeline by BioSource Pharm, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H2 2015
  • Enterococcus faecium Infections - Pipeline by ContraFect Corporation, H2 2015
  • Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015
  • Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H2 2015
  • Enterococcus faecium Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H2 2015
  • Enterococcus faecium Infections - Pipeline by Microbiotix, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Novan, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015
  • Enterococcus faecium Infections - Pipeline by Omnia Molecular Ltd., H2 2015
  • Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2015
  • Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2015
  • Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Enterococcus faecium Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Enterococcus faecium Infections - Dormant Projects, H2 2015
  • Enterococcus faecium Infections - Dormant Projects (Contd..1), H2 2015
  • Enterococcus faecium Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Enterococcus faecium Infections, H2 2015
  • Number of Products under Development for Enterococcus faecium Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top